These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 33829722)
1. Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection. Moreno-García E; Rico E; Albiach L; Agüero D; Ambrosioni J; Bodro M; Cardozo C; Chumbita M; De la Mora M; García-Pouton N; Garcia-Vidal C; González-Cordón A; Hernández-Meneses M; Inciarte A; Laguno M; Leal L; Linares L; Macay I; Meira F; Mensa J; Moreno A; Morata L; Puerta-Alcalde P; Rojas J; Solá M; Torres B; Torres M; Tomé A; Tuset M; Castro P; Fernández S; Nicolás JM; Almuedo-Riera A; Muñoz J; Fernandez-Pittol M; Marcos MA; Soy D; Martínez JA; García F; Soriano A Rev Esp Quimioter; 2021 Jun; 34(3):238-244. PubMed ID: 33829722 [TBL] [Abstract][Full Text] [Related]
2. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. Gupta S; Wang W; Hayek SS; Chan L; Mathews KS; Melamed ML; Brenner SK; Leonberg-Yoo A; Schenck EJ; Radbel J; Reiser J; Bansal A; Srivastava A; Zhou Y; Finkel D; Green A; Mallappallil M; Faugno AJ; Zhang J; Velez JCQ; Shaefi S; Parikh CR; Charytan DM; Athavale AM; Friedman AN; Redfern RE; Short SAP; Correa S; Pokharel KK; Admon AJ; Donnelly JP; Gershengorn HB; Douin DJ; Semler MW; Hernán MA; Leaf DE; JAMA Intern Med; 2021 Jan; 181(1):41-51. PubMed ID: 33080002 [TBL] [Abstract][Full Text] [Related]
3. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M; JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005 [TBL] [Abstract][Full Text] [Related]
4. Early use of tocilizumab in patients with severe pneumonia secondary to severe acute respiratory syndrome coronavirus 2 infection and poor prognostic criteria: Impact on mortality rate and intensive care unit admission. Sánchez-Rovira P; Pérez-Chica G; Ortega-Granados AL; Aguilar-García J; Díaz-Beltrán L; Gálvez-Montosa F; García-Verdejo F; Luque-Caro N; Quero-Blanco C; Fernández-Navarro M; Rodríguez-Sánchez A; Ruiz-Bailén M; Yaguez-Mateos L; Marín-Pozo JF; Sierra-Torres MI; Lacárcel-Bautista C; Duro-Ruiz GJ; Duro-Fernández MÁ; García-Alegría J; Herrero-Rodríguez C Medicine (Baltimore); 2021 Jul; 100(29):e26533. PubMed ID: 34398008 [TBL] [Abstract][Full Text] [Related]
5. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. Grasselli G; Zangrillo A; Zanella A; Antonelli M; Cabrini L; Castelli A; Cereda D; Coluccello A; Foti G; Fumagalli R; Iotti G; Latronico N; Lorini L; Merler S; Natalini G; Piatti A; Ranieri MV; Scandroglio AM; Storti E; Cecconi M; Pesenti A; JAMA; 2020 Apr; 323(16):1574-1581. PubMed ID: 32250385 [TBL] [Abstract][Full Text] [Related]
6. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study. Martínez-Sanz J; Muriel A; Ron R; Herrera S; Pérez-Molina JA; Moreno S; Serrano-Villar S Clin Microbiol Infect; 2021 Feb; 27(2):238-243. PubMed ID: 32979572 [TBL] [Abstract][Full Text] [Related]
7. Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19. Piano S; Dalbeni A; Vettore E; Benfaremo D; Mattioli M; Gambino CG; Framba V; Cerruti L; Mantovani A; Martini A; Luchetti MM; Serra R; Cattelan A; Vettor R; Angeli P; Liver Int; 2020 Oct; 40(10):2394-2406. PubMed ID: 32526083 [TBL] [Abstract][Full Text] [Related]
8. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis. Kyriakopoulos C; Ntritsos G; Gogali A; Milionis H; Evangelou E; Kostikas K Respirology; 2021 Nov; 26(11):1027-1040. PubMed ID: 34605114 [TBL] [Abstract][Full Text] [Related]
9. Cohort of Four Thousand Four Hundred Four Persons Under Investigation for COVID-19 in a New York Hospital and Predictors of ICU Care and Ventilation. Singer AJ; Morley EJ; Meyers K; Fernandes R; Rowe AL; Viccellio P; Thode HC; Bracey A; Henry MC Ann Emerg Med; 2020 Oct; 76(4):394-404. PubMed ID: 32563601 [TBL] [Abstract][Full Text] [Related]
10. The effect of tocilizumab on cytokine release syndrome in COVID-19 patients. de Cáceres C; Martínez R; Bachiller P; Marín L; García JM Pharmacol Rep; 2020 Dec; 72(6):1529-1537. PubMed ID: 33165762 [TBL] [Abstract][Full Text] [Related]
11. A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. Sarmiento-Monroy JC; Espinosa G; Londoño MC; Meira F; Caballol B; Llufriu S; Carrasco JL; Moll-Udina A; Quintana LF; Giavedoni P; Ramírez J; Inciarte-Mundo J; Solana E; Blanco Y; Martinez-Hernandez E; Sepúlveda M; Llorenç V; Prieto-González S; Espígol-Frigolé G; Milisenda JC; Cid MC; Mascaró JM; Blanco I; Barberá JA; Sibila O; Gratacos-Ginès J; Adán A; Agustí A; Sanmartí R; Panés J; Cervera R; Vila J; Soriano A; Gómez-Puerta JA; J Autoimmun; 2021 Feb; 117():102580. PubMed ID: 33338707 [TBL] [Abstract][Full Text] [Related]
12. Characteristics and Outcomes Based on Perceived Illness Severity in SARS-CoV-2. Snipelisky D; Johnson R; Prasad R; Lakhani B; Ellington J South Med J; 2020 Dec; 113(12):618-622. PubMed ID: 33263129 [TBL] [Abstract][Full Text] [Related]
13. Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis. Steuber TD; Rosandich T; Cadwallader T; Steil L; Belk M; Yendrapalli U; Hassoun A; Edwards J Ann Pharmacother; 2024 Apr; 58(4):391-397. PubMed ID: 37522616 [TBL] [Abstract][Full Text] [Related]
14. Tocilizumab in the Management of COVID-19: A Preliminary Report. Li M; Yoo EJ; Baram M; McArthur M; Skeehan C; Awsare B; George G; Summer R; Zurlo J; Jallo J; Roman J Am J Med Sci; 2021 Feb; 361(2):208-215. PubMed ID: 33358502 [TBL] [Abstract][Full Text] [Related]
15. Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison. Hamed DM; Belhoul KM; Al Maazmi NA; Ghayoor F; Moin M; Al Suwaidi M; Narainen M; Makki M; AbdulRahman M J Infect Public Health; 2021 Aug; 14(8):985-989. PubMed ID: 34153729 [TBL] [Abstract][Full Text] [Related]
16. Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2. Petrak RM; Skorodin NC; Van Hise NW; Fliegelman RM; Pinsky J; Didwania V; Anderson M; Diaz M; Shah K; Chundi VV; Hines DW; Harting BP; Sidwha K; Yu B; Brune P; Owaisi A; Beezhold D; Kent J; Vais D; Han A; Gowda N; Sahgal N; Silverman J; Stake J; Nepomuceno J; Heddurshetti R Clin Transl Sci; 2021 Nov; 14(6):2146-2151. PubMed ID: 32918792 [TBL] [Abstract][Full Text] [Related]
18. Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis. Urbina T; Lavillegrand JR; Garnier M; Mekinian A; Pacanowski J; Mario N; Dumas G; Hariri G; Pilon A; Darrivère L; Fartoukh M; Guidet B; Maury E; Leblanc J; Chantran Y; Fain O; Lacombe K; Voiriot G; Ait-Oufella H Innate Immun; 2022 Jan; 28(1):3-10. PubMed ID: 35089113 [TBL] [Abstract][Full Text] [Related]
19. In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation. Olivas-Martínez A; Cárdenas-Fragoso JL; Jiménez JV; Lozano-Cruz OA; Ortiz-Brizuela E; Tovar-Méndez VH; Medrano-Borromeo C; Martínez-Valenzuela A; Román-Montes CM; Martínez-Guerra B; González-Lara MF; Hernandez-Gilsoul T; Herrero AG; Tamez-Flores KM; Ochoa-Hein E; Ponce-de-León A; Galindo-Fraga A; Kershenobich-Stalnikowitz D; Sifuentes-Osornio J PLoS One; 2021; 16(2):e0245772. PubMed ID: 33534813 [TBL] [Abstract][Full Text] [Related]
20. The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials. Lin WT; Hung SH; Lai CC; Wang CY; Chen CH Int Immunopharmacol; 2021 Jul; 96():107602. PubMed ID: 33812260 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]